Edition:
United Kingdom

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

0.99USD
18 Dec 2018
Change (% chg)

-- (--)
Prev Close
$0.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
94,611
52-wk High
$3.30
52-wk Low
$0.47

Latest Key Developments (Source: Significant Developments)

Bellerophon Therapeutics Q3 Earnings Per Share $0.19
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.19.  Full Article

Bellerophon Therapeutics Inc - Qtrly reports loss per share at $0.10
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.10.BELLEROPHON - ABILITY TO ACCESS FUNDING IS LIKELY TO BE INFLUENCED BY RESULTS OF ONGOING PHASE 2B TRIAL OF INOPULSE FOR PH-ILD.BELLEROPHON SAYS ABILITY TO ACCESS FUNDING IN ANY FORM IS NOT ASSURED.  Full Article

Bellerophon Therapeutics Inc Files For Mixed Shelf Of Up To $100 mln
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING.  Full Article

Bellerophon Q4 Loss Per Share $0.44
Thursday, 15 Mar 2018 

March 15 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.44.  Full Article

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article